Updated:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases
Dr. Lindsey Criswell directs the $625M NIAMS research budget at NIH, funding bone, joint, muscle, and skin disease science since 1986.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases
The National Institute of Arthritis and Musculoskeletal and Skin Diseases was established in 1986 as part of the National Institutes of Health. Dr. Lindsey A. Criswell, a rheumatologist and geneticist, has led the institute since 2021. The institute's funding is sourced entirely from annual congressional appropriations, which it deploys through a rigorous peer-reviewed extramural grant program and a dedicated intramural research division on the NIH campus in Bethesda, Maryland. NIAMS supports the full spectrum of research, from basic laboratory science to late-stage clinical trials. Its extramural program funds investigators at universities and research hospitals across all 50 states, with an annual budget of roughly $625 million. The portfolio spans molecular biology of cartilage degradation, genomics of lupus, clinical trials for new psoriasis biologics, and health disparities research in osteoarthritis. Key funded milestones include the development of TNF inhibitors for rheumatoid arthritis and the genetic mapping of ankylosing spondylitis. The institute also runs a centralized intramural program where NIH-based scientists conduct longitudinal studies on diseases like lupus and myositis. With no permanent endowment, NIAMS operates entirely on fiscal-year appropriations. Its influence is measured in outputs rather than assets: the institute funded over 1,800 research grants in fiscal year 2023 and supports the NIH Osteoporosis and Related Bone Diseases National Resource Center. It coordinates closely with sister institutes like the National Institute of Allergy and Infectious Diseases on autoimmune conditions that cross tissue boundaries. Dr. Criswell has prioritized initiatives in health disparities and the NIH Accelerating Medicines Partnership in rheumatoid arthritis and lupus. NIAMS is structurally distinct from a private foundation. Its congressional mandate and embedded government status mean its research priorities must align with public health needs identified by the Department of Health and Human Services, creating a unique tension between investigator-initiated science and directed federal health policy. The institute does not manage a portfolio for financial return — its return is measured in published science and new therapies.
General information
Firm type
Foundation
Year founded
1986
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bethesda
Corporate office
Bethesda, MD, United States
Principals
Lindsey A. Criswell
Director
Sector focus
Frequently asked questions
What is the relationship between NIAMS and the broader National Institutes of Health?
NIAMS is one of 27 institutes and centers that make up the National Institutes of Health, a part of the U.S. Department of Health and Human Services. It receives its funding through annual congressional appropriations and operates both an extramural grant-making program and an intramural research division on the NIH campus in Bethesda, Maryland.
Who sets the research priorities for NIAMS?
The institute director, currently Dr. Lindsey Criswell, sets the scientific priorities in consultation with the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council. The council includes public members and scientific experts who review the institute's portfolio and advise on strategic direction. These priorities are also shaped by the NIH-wide strategic plan and congressional mandates.
How does NIAMS distribute its research funding?
Roughly 80% of NIAMS funding supports extramural research at universities, teaching hospitals, and independent research organizations across the United States. Grants are awarded through a competitive, peer-reviewed process managed by the NIH Center for Scientific Review. The remaining approximate 20% supports the institute's own intramural laboratories and clinical research programs on the NIH campus.
What types of diseases fall under NIAMS' mandate?
The institute's scope covers diseases of the bones, joints, muscles, and skin. This includes rheumatoid arthritis, osteoarthritis, lupus, scleroderma, psoriasis, eczema, muscular dystrophy, osteogenesis imperfecta, osteoporosis, and acne, among others. It does not cover neurological muscle diseases such as ALS, which fall under the National Institute of Neurological Disorders and Stroke.
Does NIAMS conduct its own clinical trials, or only fund university-based ones?
Both. The NIAMS Intramural Research Program runs dedicated natural history studies and early-phase clinical trials focused on rare and complex rheumatic, musculoskeletal, and skin diseases. Simultaneously, the extramural program funds multi-center clinical trials through investigator-initiated grants. One active intramural focus is the study of hidradenitis suppurativa and its systemic comorbidities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: